Clinical Trials

Phase 1/2 Active not recruiting

Leukemia, Lymphoma, Neoplasms, Recurrence

NCT07134088 2026-05-15

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

104 enrolled

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

306 enrolled

Phase 1 Not yet recruiting

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

NCT07586618 2026-05-14

ALT-101

24 enrolled

Leukemia, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06634589 2026-05-11

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

80 enrolled

Phase 1 Active not recruiting

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT05784441 2026-05-08

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

21 enrolled

Recurrence, Lymphoma, B-Cell

NCT07123454 2026-05-08

Lumi-NHL

91 enrolled

Phase 2/3 Active not recruiting

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT04442022 2026-05-06

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

501 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05283720 2026-05-06

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05896163 2026-05-06

MAPtivate-6

Phase 1/2 Terminated

40 enrolled

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06149286 2026-05-06

OLYMPIA-5

470 enrolled

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT07453446 2026-05-06

Clinical Study of U29 Injection (CD30-CART) in Patients With CD30-Positive Relapsed/Refractory Lymphoma

Phase 1 Withdrawn

Phase 3 Active not recruiting

Lymphoma, Recurrence

NCT04712097 2026-05-05

Celestimo

478 enrolled

Lymphoma, Follicular, Recurrence

NCT04771572 2026-05-05

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

LymphoidMyeloidOther hematologic neoplasmPlasma cell

100 enrolled

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT06970496 2026-05-05

A Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.

Phase 1 Not yet recruiting

48 enrolled

Recurrence, Lymphoma, B-Cell

NCT06132503 2026-05-04

Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors

110 enrolled

LymphoidSarcoma

Lymphoma, Neoplasms, Recurrence, Sarcoma

NCT04521231 2026-05-01

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

281 enrolled

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04588922 2026-05-01

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

160 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06035497 2026-05-01

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

85 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT06542250 2026-05-01

TITANium

174 enrolled

Lymphoma, Follicular, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT06854653 2026-04-29

A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL

Phase 2 Recruiting

115 enrolled

DermatologicLymphoid

Lymphoma, Non-Hodgkin, Mycosis Fungoides, Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT07082686 2026-04-27

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Phase 2 Recruiting

75 enrolled

Recurrence, Lymphoma, Mantle-Cell

NCT04094311 2026-04-20

Study of Out of Specification for Tisagenlecleucel

200 enrolled

Phase 3 Active not recruiting

Burkitt Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05888493 2026-04-17

LEDA

109 enrolled

Lymphoma, Follicular, Recurrence

NCT06761586 2026-04-17

VIJAY-1

Phase 1 Terminated

9 enrolled

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT03328078 2026-04-16

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

152 enrolled

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Recurrence, Hematologic Neoplasms

NCT07523555 2026-04-13

ADAPT-HEM

LymphoidMyeloidOther hematologic neoplasmPlasma cell

96 enrolled

Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Lymphoma, Leukemia, Plasma Cell, Multiple Myeloma, Recurrence, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02625480 2026-04-09

ZUMA-4

Phase 1/2 Completed

95 enrolled

Recurrence, Lymphoma, B-Cell

NCT04049825 2026-04-08

A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Phase 1 Completed

36 enrolled

Phase 1/2 Active not recruiting

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT04404660 2026-04-08

A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)

153 enrolled 1 FDA

Burkitt Lymphoma, Recurrence

NCT06522737 2026-04-06

TERZO

124 enrolled

Phase 2 Active not recruiting

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Lymphoma, T-Cell, Peripheral

NCT05020015 2026-03-31

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

27 enrolled 23 charts

Phase 1 Active not recruiting

Recurrence, Lymphoma, B-Cell

NCT05753501 2026-03-27

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

135 enrolled

Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Hematologic Neoplasms, Lymphoma, Mantle-Cell

NCT07082803 2026-03-27

TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas

180 enrolled

Phase 1 Active not recruiting

Lymphoma, Lymphoma, Non-Hodgkin, Recurrence

NCT04756726 2026-03-25

Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma

224 enrolled

LymphoidPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Recurrence

NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

LymphoidMyeloidOther hematologic neoplasmPlasma cell

606 enrolled

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06189391 2026-03-19

MK-1045-001

100 enrolled